| Literature DB >> 21473769 |
Nadia S Metwally1, Sanaa A Ali, Azza M Mohamed, Hussein M Khaled, Samia A Ahmed.
Abstract
BACKGROUND/Entities:
Year: 2011 PMID: 21473769 PMCID: PMC3097143 DOI: 10.1186/1475-2867-11-8
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
Serum tumor markers in bilharzial and non-bilharzial bladder cancer patients compared to normal (unaffected) patients
| Parameters | Control | Bilharzial bladder | non-bilharzial | ANOVA |
|---|---|---|---|---|
| 1. XO (μmol uric acid/min/ml) | 0.3 ± 0.05 | 2.77 ± 0.33 | 1.58 ± 0.23 | P < 0.0001 |
| 2. Fructosamine (μmol/L) | 337.88 ± 34.4 | 1145.27 ± 146.16 | 742.3 ± 132.44 | P < 0.0001 |
| 3. hydroxylproline (μg/ml) | 23.35 ± 2.83 | 78.56 ± 10.48 | 46.06 ± 4.28 | P < 0.0001 |
| 4. IgE (IU/ml) | 44.37 ± 1.66 | 301.49 ± 14.04 | 269.0 ± 7.66 | P < 0.0001 |
| 5. TNF-∝ (Pg/ml) | 7.8 ± 0.22 | 37.7 ± 1.61 | 24.6 ± 0.84 | P < 0.0001 |
Data are represented as mean ± SD of 10 control and 30 patients (15 patients bilharzial and 15 non-bilharzial)
Serum enzymes in bilharzial and non-bilharzial bladder cancerous patients in comparison to healthy persons:
| Parameters | Grading progress | Healthy cases | Bilharzial bladder cancerous patients | non-bilharzial bladder cancerous patients | ||||
|---|---|---|---|---|---|---|---|---|
| I | II | III | I | II | III | |||
| n = 10 | n = 4 | n = 5 | n = 6 | n = 6 | n = 4 | n = 5 | ||
| AST (U/L) | Mean ± S.D | 28.4 ± 2.3 | 102.7 ± 6.9 | 120.6 ± 8.5 | 132.9 ± 10.1 | 85.3 ± 4.9 | 96.5 ± 9.3 | 107.3 ± 11.6 |
| P < | -- | H.S | H.S | H.S | H.S | H.S | H.S | |
| ALT (U/L) | Mean ± S.D | 26.3 ± 1.8 | 82.2 ± 3.95 | 96.5 ± 6.1 | 111.1 ± 9.9 | 69.3 ± 6.5 | 83.3 ± 7.6 | 99.8 ± 6.7 |
| P< | -- | H.S | H.S | H.S | H.S | H.S | H.S | |
| LDH (U/L) | Mean ± S.D | 139.9 ± 13.8 | 351.5 ± 20.2 | 434.7 ± 21.4 | 489.3 ± 37.6 | 334.4 ± 15.5 | 379.1 ± 14.2 | 408.6 ± 14.2 |
| P< | -- | H.S | H.S | H.S | H.S | H.S | H.S | |
| Total protein gm% | Mean ± S.D | 7.7 ± 0.5 | 8.30 ± 0.6 | 8.40 ± 0.4 | 9.30 ± 0.3 | 7.40 ± 0.3 | 7.5 ± 0.4 | 7.80 + 0.5 |
| P < | -- | S | S | S | N.S | N.S | N.S | |
H.S: P < 0.0005 N.S: P < 0.02
Tumor marker enzymes in bilharzial and non-bilharzial carcinoma tissues compared to normal (unaffected) tissues:
| Enzymes | Tissues types | Bilharzial bladder cancerous tissues n = 13 | Bladder cancerous tissues n = 12 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unaffected (normal) tissues | Malignant tissues | Unaffected (normal) tissues | Malignant tissues | ||||||||||
| Grading | I | II | III | I | II | III | I | II | III | I | II | III | |
| LDH | Mean ± SD | 8.5 ± 0.33 | 8.8 ± 0.21 | 9.1 ± 0.12 | 15.4 ± 0.2 | 16.3 ± 0.21 | 17.3 ± 0.17 | 6.1 ± 0.14 | 6.9 ± 0.24 | 7.2 ± 0.17 | 10.8 ± 0.5 | 12.5 ± 0.29 | 13.5 ± 0.3 |
| P< | -- | -- | -- | H.S | H.S | H.S | -- | -- | -- | H.S | H.S | H.S | |
| AST | Mean ± SD | 1.74 ± 0.038 | 1.91 ± 0.01 | 2.06 ± 0.30 | 2.85 ± 0.05 | 3.44 ± 0.1 | 3.91 ± 0.13 | 1.61 ± 0.01 | 1.76 ± 0.04 | 1.93 ± 0.1 | 2.78 ± 0.03 | 3.19 ± 0.02 | 3.58 ± 0.13 |
| P< | - | - | -- | H.S | H.S | H.S | -- | -- | -- | H.S | H.S | H.S | |
| ALT | Mean ± SD | 4.69 ± 0.04 | 4.82 ± 0.05 | 4.98 ± 0.1 | 7.73 ± 0.3 | 7.96 ± 0.57 | 8.22 ± 0.4 | 4.59 ± 0.05 | 4.77 ± 0.13 | 4.86 ± 0.14 | 7.53 ± 0.02 | 7.82 ± 0.02 | 7.97 ± 0.03 |
| P< | -- | -- | -- | H.S | H.S | H.S | - | -- | -- | H.S | H.S | H.S | |
| PK | Mean ± SD | 15.10 ± 3.70 | 15.21 ± 3.79 | 15.32 ± 3.81 | 36.1 ± 10.3 | 38.4 ± 12.6 | 42.3 ± 14.7 | 14.81 ± 3.12 | 14.97 ± 3.24 | 15.30 ± 3.51 | 24.90 ± 4.70 | 27.0 ± 10.6 | 30.1 ± 11.34 |
| P< | -- | -- | -- | H.S | H.S | H.S | -- | -- | -- | H.S | H.S | H.S | |
Activities were expressed as μ moles/mm/g tissue
H.S: Significant difference P <0 .0005
Essential amino acid fractions in different groups of bladder cancer and bilharzial bladder cancer patients
| Parameters | Control | Bladder cancer | Bilharzial bladder cancer | % Change | ||
|---|---|---|---|---|---|---|
| (a) | (b) | (c) | ||||
| Isoleucine | 2.75 ± 0.390 | 5.27 ± 1.24 | 5.3 ± 0.89 | +92 | +52 | +90 |
| Leucine | 5.36 ± 0.397 | 9.73 ± 2.88 | 9.99 ± 1.82 | +81 | +29 | +86 |
| Threonine | 7.70 ± 1.175 | 9.78 ± 3.30 | 8.3 ± 2.63 | +27 | -37 | +8 |
| Valine | 3.15 ± 0.83 | 10.28 ± 4.43 | 11.6 ± 2.32 | +226 | +51 | +267 |
| Phenylalanine | 3.12 ± 0.46 | 5.07 ± 1.07 | 4.7 ± 0.78 | +62 | +31 | +51 |
| 1-Methyl-Histidine | 5.22 ± 0.58 | 7.48 ± 1.167 | 6.7 ± 2.27 | +43 | +36 | +29 |
| Lysine | 8.56 ± 1.43 | 16.59 ± 3.98 | 16.9 ± 3.22 | +94 | +75 | +97 |
| Trytophan | 1.34 ± 0.39 | 0.000 ± 0.00 | 1.5 ± 1.35 | -100 | -66 | +15 |
| Carnosine | 2.84 ± 0.58 | 1.18 ± 0.62 | 2.1 ± 0.71 | -58 | -41 | -26 |
| Cystathionine | 0.923 +0.59 | 0.153+0.14 | 0.47 +0.99 | -83 | -84 | -49 |
• Data are means ± S.D. of five patients in each group.
• Total amino acid is expressed as g/L serum.
• (a, b and c) percentage change as compared with control.
Non-essential free amino acid fractions in different groups of bladder cancer and bilharzial bladder cancer patients
| Parameters | Control | Bladder cancer | Bilharzial bladder cancer | % Change | ||
|---|---|---|---|---|---|---|
| (a) | (b) | (c) | ||||
| Asparatic acid | 2.61 ± 1.07 | 5.399 ± 2.230 | 14.141 ± 10.35 | +106.78 | +29 | +442 |
| Proline | 4.46 ± 0.24 | 14.84 ± 5.37 | 10.227 ± 3.13 | +232.5 | +177 | +129 |
| Glycine | 14.14 ± 2.72 | 9.19 ± 1.22 | 6.917 ± 4.55 | -35 | -99.98 | -51 |
| Alanine | 1.09 ± 0.23 | 19.75 ± 7.43 | 14.421 ± 3.34 | +1703 | +1457 | +1216 |
| Serine | 7.98 ± 0.81 | 12.03 ± 3.15 | 8.977 ± 2.20 | +51 | +19 | +13 |
| Glutamic acid | 31.38 ± 3.16 | 35.32 ± 4.64 | 44.53 ± 14.03 | +13 | +33 | +42 |
| Tyrosine | 4.23 ± 0.35 | 5.92 ± 1.91 | 6.455 ± 0.79 | +40 | +40 | +53 |
| NH4+ | 4.23 ± 1.16 | 9.43 ± 1.94 | 5.955 ± 2.74 | +123 | +11 | +41 |
| Phosphoserin | 0.19 ± 0.06 | 0.24 ± 0.086 | 0.280 ± 0.21 | +27 | -1.1 | +49 |
| Taurin | 3.35 ± 0.49 | 6.53 ± 1.69 | 3.075 ± 0.23 | +95 | -18 | -8 |
| Urea | 76.5 ± 9.86 | 88.28 ± 7.24 | 111.95 ± 9.32 | +15 | + 5 | +46 |
| Cystine | 3.22 ± 0.57 | 3.99 ± 0.81 | 3.884 ± 1.15 | +24 | -37 | +21 |
| Citrulline | 0.96 ± 0.41 | 1.51 ± 0.36 | 1.198 ± 0.41 | +147 | -42 | +24 |
| Ornithine | 4.396 ± 0.71 | 11.114 ± 3.42 | 5.467 ± 0.81 | +153 | +75 | +24 |
| Arginine | 3.58 ± 0.71 | 7.72 ± 1.23 | 27.3 ± 3.01 | +115 | +289 | +663 |
| a-Aminobutyric acid | 0.0197 ± 0.01 | 0.188 ± 0.32 | 0.0010 ± 0.001 | +854 | +28 | -95 |
| a-Aminoadipic acid | 1.530 ± 0.29 | 0.0012 ± 0.002 | 0.282 ± 0.261 | -99.9 | -100 | -82 |
• Data are means ± S.D. of five patients in each group.
• Total amino acid is expressed as g/L serum.
• (a, b and c) percentage change as compared with control.